In the 💊 discovery process, high throughput screening (HTS) allows quick and efficient screening of large compound libraries… provided you have access to these compounds.
When it comes to proteins, transient gene expression (TGE) is a fast and “relatively” simple way to produce the needed amounts of each of the compounds to be screened.
“Relatively” because it depends on several factors,
👉The cell line you will select
👉 The cultivation, transfection and production protocols you will deploy
👉The media you will use
👉 The skills you will develop
are, among other factors, the most important.
We at Magellan Biologics & Consulting can support you making the right choices with CHO4Tx®, our dedicated and integrated solution for in-house TGE including:
👉 The CHO 4Tx® cell line
👉 The CHO 4Tx® protocol in just 3 steps with only 3 media
👉 Our 3 media: CHO 4Tx® CM for cell cultivation, CHO 4Tx® TM for cell transfection and CHO 4Tx® PM for protein production
👉Last… but not least! full support from our CHO 4Tx® experts who will advise and help you getting the best out of your TGE process, making it easy, efficient and cost effective.
A novel drug produced in CHO cells has recently been approved by the FDA
Tislelizumab-jsgr is a PD-1 blocking antibody indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic
29 March 2024
